Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEMARA trial of bemarituzumab-based therapy in FGFR2b-positive advanced gastric or gastroesophageal junction adenocarcinoma
2024-512484-31-00Phase 2Authorised
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of bemarituzumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 cohorts), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective response rate. Planned start Feb 2025; status: authorised.
02
Drugs
bemarituzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-512484-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512484-31-00.